close-icon

MHQ: Clinical IntelligencePowered by SurvivorNet

  • health-panel

    Health Panel

  • clinical-trial

    Clinical Trials

    ?
Prefer to talk instead of typing?
close-icon

Answers offered are informational and do not constitute medical advice. Learn more

close-icon
Health Profile

Enter health info to personalize results.

What is your gender?

What is your age?

close-icon
Clinical Trials

clinical-icon

filter

Clear List

Ask me anything about your health...

I’m listening

thinking

responding

close-icon close-icon
close-icon
close-icon
close-icon
left-icon Back to Results

Dr. Oliver Dorigo

location-icon

Stanford, CA

LOCATION OF PRACTICE
Stanford University Medical Center
MEDICAL Specialty:

Ovarian Cancer



NPI Number
1306873294
ABOUT

Oliver Dorigo, MD, PhD is the Director of the Stanford Gynecologic Oncology Fellowship, the Director of Stanford Clinical Research Group for Gynecologic Cancer Trials, and the Director of Stanford Gynecologic Oncology Clinical Care Program.

Dr. Oliver Dorigo profile image

Published Articles

Ovarian Cancer Ascites Enriched for CCL23 Reduces Macrophage-Derived CXCL10 Secretion and Is Associated with Poor Patient Outcomes.- 2025 Dec 8
Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.- 2026 Feb 17
Durable response to an anti-CD25 antibody-drug conjugate and anti-PD-1 antibody in ovarian carcinoma: a case report.- 2025 Sep
Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma.- 2025 Apr 18
Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer.- 2025 Jun
Clinical Response to Enfortumab Vedotin and Pembrolizumab in a Patient with Vaginal Squamous Cell Carcinoma: A Case Report.- 2025 Jan-Dec
Long term treatment of advanced endometrial cancer with lenvatinib and pembrolizumab.- 2025 Apr
Fertility-sparing treatment for atypical polypoid adenomyoma.- 2025 Apr
Presentation and Management of Highly Differentiated Follicular Carcinoma of Ovarian Origin With DICER1 Gene Variants.- 2024 Dec
Trends in ovarian, fallopian tube, and primary peritoneal cancer incidence, mortality, and survival: A 15-year population-based analysis.- 2024 May

Clinical Trials

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN
Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

My Patient Resources

Other Specialists treating Ovarian Cancer in Stanford, CA

See All Doctors

Dr. Jonathan Berek

Specialty: Gynecology

My Resources
location-icon

Stanford Medicine

My Resources

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider